CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


SARS-Cov-2 infectionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1817 Physiotherapy Wiki 0.71

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Patterns and Changes in Platelet Reactivity, Thrombotic Status and Endothelial Function in Hospitalized Patients With SARS-Cov-2 Infection

The present study is ideated to prospectively investigate in patients with severe acute respiratory syndrome (SARS) due to Coronavirus 19 (SARS-Cov-2) infection and moderate-severe respiratory failure the patterns and changes in platelet reactivity, thrombotic status and endothelial function. The observed patterns and changes will be related with inflammatory status, myocardial injury and outcomes

NCT04343053 Severe Acute Respiratory Syndrome Coronavirus 2 Other: SARS-Cov-2 infection
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: patterns and changes of platelet aggregation values assessed by light transmission aggregometry after arachidonic acid, adenosine diphosphate and thrombin receptor activating peptide stimuli

Measure: on-treatment platelet reactivity

Time: early stage of disease (first 96 hours)

Description: patterns and changes of platelet aggregation values assessed by light transmission aggregometry after arachidonic acid, adenosine diphosphate and thrombin receptor activating peptide stimuli

Measure: on-treatment platelet reactivity

Time: mid stage of disease (96 hours - 14 days)

Description: patterns and changes of platelet aggregation values assessed by light transmission aggregometry after arachidonic acid, adenosine diphosphate and thrombin receptor activating peptide stimuli

Measure: on-treatment platelet reactivity

Time: late stage of disease (>14 days)

Secondary Outcomes

Description: patterns and changes of the rate of apoptosis in HUVEC incubated with serum from patients enrolled in the study.

Measure: apoptosis rate in human umbilical vein endothelial cells (HUVEC)

Time: early stage of disease (first 96 hours)

Description: patterns and changes of the rate of apoptosis in HUVEC incubated with serum from patients enrolled in the study.

Measure: apoptosis rate in human umbilical vein endothelial cells (HUVEC)

Time: mid stage of disease (96 hours - 14 days)

Description: patterns and changes of intracellular level of NO in HUVEC incubated with serum from patients enrolled in the study.

Measure: Nitric oxide (NO) intracellular levels

Time: late stage of disease (>14 days)

Description: patterns and changes of intracellular level of NO in HUVEC incubated with serum from patients enrolled in the study.

Measure: Nitric oxide (NO) intracellular levels

Time: early stage of disease (first 96 hours)

Description: patterns and changes of intracellular level of NO in HUVEC incubated with serum from patients enrolled in the study.

Measure: Nitric oxide (NO) intracellular levels

Time: mid stage of disease (96 hours - 14 days)

Description: patterns and changes of ROS

Measure: reactive oxygen species (ROS) levels

Time: early stage of disease (first 96 hours)

Description: patterns and changes of ROS

Measure: reactive oxygen species (ROS) levels

Time: mid stage of disease (96 hours - 14 days)

Description: patterns and changes of ROS

Measure: reactive oxygen species (ROS) levels

Time: late stage of disease (>14 days)

Description: patterns and changes of the most important coagulation factors (i.e. tissue factor antigen pg/dL)

Measure: coagulation factors levels

Time: early stage of disease (first 96 hours)

Description: patterns and changes of the most important coagulation factors (i.e. tissue factor antigen pg/dL)

Measure: coagulation factors levels

Time: mid stage of disease (96 hours - 14 days)

Description: patterns and changes of the most important coagulation factors (i.e. tissue factor antigen pg/dL)

Measure: coagulation factors levels

Time: late stage of disease (>14 days)

Description: values of FEV1% as assessed by spirometry

Measure: respiratory function

Time: 6-month

Description: values of FEV1% as assessed by spirometry

Measure: respiratory function

Time: 12-month

Description: values of left ventricular ejection fraction as assessed by transthoracic echocardiogram

Measure: cardiac function

Time: 6-month

Description: values of left ventricular ejection fraction as assessed by transthoracic echocardiogram

Measure: cardiac function

Time: 12-month

Description: occurrence of death, myocardial infarction, stroke and other major adverse events

Measure: clinical outcome

Time: 12-month


No related HPO nodes (Using clinical trials)